AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00001024
Drug: Didanosine
RxNorm normalized name: Didanosine
DrugBank: Didanosine (DB00900)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05509933
Drug: Budesonide
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: budesonide starting day 5 after transplant
Trial: NCT05664906
Drug: Chinese Medicine Oral Rinse Formula-I (CMORF-I)
RxNorm normalized name: iobenguane I-131
DrugBank: Iobenguane (DB06704)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Prescription of Chinese Medicine Oral Rinse Formula-I (CMORF-I)~* Instruction to rinse:~  1. The above amount of concentrated CM granules will be divided and packed in 4 bags per day.~ 2. Dissolve 1 bag of concentrated CM granules with 150ml 80'C boiled hot water, and wait for 20 mins to cool down.~ 3. Clean the mouth thoughtfully by rinsing with 150ml of distilled water for 2 minutes.~ 4. Rinse the mouth thoughtfully with one-third of the dissolved and cooled CM oral rinse, gargle, expel after 3 minutes, do not swallow and repeat twice.~ 5. To ensure better contact of the CM oral rinse in all parts and folds of the oral cavity, our research assistant and CMP will guide the patients to fully agitate the mouth, use the tongue to stir repeatedly among the teeth, cheeks and palate surface, and to raise the tip of the tongue for a moment and tilt the head back.~ 6. 4 times a day (half an hour after every meal, half an hour before sleep), from baseline to 2 weeks after RT.
Trial: NCT05355155
Drug: Bevacizumab Biosimilar IBI305
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients received bevacizumab and FOLFOX4 every two weeks
Trial: NCT05232123
Drug: Cannabidiol
RxNorm normalized name: CANNABIDIOL
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cannabidiol oral product formulated in MCT (medium chain triglyceride) oil
Trial: NCT04908462
Drug: AL01211 or Placebo (Part A)
RxNorm normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Five dose groups with doses ranging from 2mg to 60 mg
Trial: NCT04908462
Drug: AL01211 or Placebo (Part B)
RxNorm normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Five dose groups with doses ranging from 2-60 mg daily. Each separate dose given for 14 days
Trial: NCT00001061
Drug: Sevirumab
RxNorm normalized name: Sevirumab
DrugBank: Sevirumab (DB17771)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00001061
Drug: Foscarnet sodium
RxNorm normalized name: Foscarnet Sodium
DrugBank: Foscarnet (DB00529)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00001061
Drug: Ganciclovir
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04953156
Drug: Nitroglycerin
RxNorm normalized name: Nitroglycerin
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: data will be retrieved from intraoperative medical records for the period from May 2020 to May 2021 for patients meeting the eligibility criteria who developed uncontrolled elevation of their blood pressure and received nitroglycerine infusion
Trial: NCT04953156
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: All patients who develop uncontrolled elevation of their blood pressure and meeting the eligibility criteria from July 2021 to July 2022 will receive dexmedetomidine bolus of 1mic/kg over 20 minutes and then continuous infusion of 0.2-0.7 mic/kg/hour adjusted according to each patient hemodynamic response.
Trial: NCT05169021
Drug: Amlodipine+intensive antihypertensive therapy
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine tablet 5.8mg, taken daily, in the morning after waking.~To achieve target blood pressure (SBP: 130-140 mmHg), this study will provide, if needed, concurrent antihypertensive medications. Patients will be asked to discontinue all prior concurrent medications. Recommended treatment options are described below:~1. Add candesartan 4mg;~2. Add indapamide 2.5mg;~3. Increase dose of candesartan to 8mg;~4. Increase dose of amlodipine to 7.5mg-10mg.
Trial: NCT05169021
Drug: Amlodipine+standard antihypertensive therapy
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine tablet 5.8mg, taken daily, in the morning after waking.~To achieve target blood pressure (SBP: 130-140 mmHg), this study will provide, if needed, concurrent antihypertensive medications. Patients will be asked to discontinue all prior concurrent medications. Recommended treatment options are described below:~1. Add candesartan 4mg;~2. Add indapamide 2.5mg;~3. Increase dose of candesartan to 8mg;~4. Increase dose of amlodipine to 7.5mg-10mg.
Trial: NCT05441280
Drug: pimavanserin
RxNorm normalized name: Pimavanserin
DrugBank: Pimavanserin (DB05316)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: pimavanserin 34mg PO at bedtime
Trial: NCT05217654
Drug: Dapagliflozin 10mg
RxNorm normalized name: DAPAGLIFLOZIN 10MG TAB
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Daily orally administration of 10mg dapagliflozin
Trial: NCT05033132
Drug: Balstilimab
RxNorm normalized name: Balstilimab
DrugBank: Balstilimab (DB15676)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-programmed cell death protein 1 (anti-PD-1) monoclonal antibody
Trial: NCT05033132
Drug: Balstilimab + Zalifrelimab
RxNorm normalized name: Zalifrelimab
DrugBank: Zalifrelimab (DB15632)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An anti-PD-1 monoclonal antibody in combination with a cytotoxic T-lymphocyte antigen-4 (CTLA-4) antibody
Trial: NCT05793892
Drug: Lidocaine tetracaine cream
RxNorm normalized name: lidocaine / tetracaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The test drug and the control drug will be uniformly spread over the treatment area using a tongue platula to form a thin layer of approximately 1 mm,right then left . The drug remained in the treatment area for 30 minutes (± 2 minutes) .
Trial: NCT05159882
Drug: THR-1442 and Dapagliflozin placebo
RxNorm normalized name: metformin and dapagliflozin
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: THR-1442 tablets 20mg and Dapagliflozin tablets placebo
Trial: NCT05159882
Drug: Dapagliflozin 10mg and THR1442 placebo
RxNorm normalized name: dapagliflozin 10 MG
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dapagliflozin tablets 10mg and THR-1442 tablets placebo
Trial: NCT04905147
Drug: Mosapride
RxNorm normalized name: mosapride
DrugBank: Mosapride (DB11675)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mosapride citrate is prokinetic drug that selectively activates 5-HT4receptors. Mosapride stimulates serotonin receptor in the digestive tract and increases acetylcholine release to promote upper digestive tract (stomach and duodenum) and lower digestive tract (colon) motility and gastric emptying without cardiac side effects
Trial: NCT05263193
Drug: Caplacizumab
RxNorm normalized name: caplacizumab
DrugBank: Caplacizumab (DB06081)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: as in real world practice
Trial: NCT05900882
Drug: Selinexor
RxNorm normalized name: Selinexor
DrugBank: Selinexor (DB11942)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Selinexor 60 mg/day, orally on d1,8,15,22
Trial: NCT05900882
Drug: Bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bortezomib 1.3mg/m2 intravenously on d1,8,15,22
Trial: NCT05900882
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenalidomide 25 mg/d (the dose will be adjusted according to creatinine clearance)
Trial: NCT05900882
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone 20 mg/day orally on d1-2, d8-9,d15-16,d22-23
Trial: NCT06447636
Drug: Surufatinib
RxNorm normalized name: Surufatinib
DrugBank: Surufatinib (DB15106)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surufatinib: 250mg qd，d1-21, q3w
Trial: NCT06447636
Drug: Sintilimab
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sintilimab：200mg ivdrip, d1, q3w
Trial: NCT06447636
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 130mg/m2，iv drip for 2h，d1, q3w
Trial: NCT06447636
Drug: S1
RxNorm normalized name: LS11
DrugBank: LS11 (DB05918)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S1：40\~60mg Bid，d1\~14, q3w
Trial: NCT06492629
Drug: Toripalimab
RxNorm normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion, 240mg, administered once every 3 weeks, until the subject has been treated for 2 years, disease progression occurs, intolerable toxic reactions are experienced, or treatment is discontinued for other reasons.
Trial: NCT06492629
Drug: chidamide
RxNorm normalized name: Chidamide
DrugBank: Tucidinostat (DB06334)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Take 30 mg (6 tablets) each time, and take the medication twice a week, with at least 3 days between doses (such as on Monday and Thursday, Tuesday and Friday, Wednesday and Saturday, etc.), to be taken 30 minutes after meals.
Trial: NCT04840641
Drug: Flucloxacillin
RxNorm normalized name: Flucloxacillin
DrugBank: Flucloxacillin (DB00301)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healthy volunteers will take 2x500 mg flucloxacillin 3 times a day for 31 days. The investigators will measure the baseline concentration of the 6-cocktaildrugs and flucloxacillin before start of 31 days of flucloxacillin treatment. On day 9 and 27 the investigators will measure the concentration of flucloxacillin. On day 10 and 28 the investigators will measure the concentration of the 6 cocktaildrugs
Trial: NCT05796791
Drug: Ketamine Hydrochloride
RxNorm normalized name: Ketamine Hydrochloride
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IM ketamine given in weekly session for a total of 3 weeks
Trial: NCT06201065
Drug: Lenvatinib
RxNorm normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 12 mg (or 8 mg) once daily (QD) oral dosing
Trial: NCT06201065
Drug: Toripalimab
RxNorm normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 240 mg iv.drip Q3W
Trial: NCT06036979
Drug: Intravenous morphine, ketorlac and paracetamol
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: • In the control group only we add 10mg intravenous morphine, 30 mg intravenous ketorlac and 1 gm intravenous paracetamol for analgesia.
Trial: NCT05432778
Drug: Letermovir Pill
RxNorm normalized name: letermovir Pill
DrugBank: Letermovir (DB12070)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients in the Study Group will receive virostatic prophylaxis with letermovir 480 mg qd (We will be utilizing Letermovir oral formulation of 240 mg or 480 mg as available). n all patients the virostatic prophylaxis will be initiated between days 4 and 7 after heart transplantation and the duration of virostatic prophylaxis will be determined by the Quantiferon-CMV assay.
Trial: NCT04929548
Drug: Pyrotinib Maleate Tablets
RxNorm normalized name: maleate
DrugBank: Pyrotinib (DB14993)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Addition of Pyrotinib in the EC phase to the standard treatment EC-THP regimen recommended by the guidelines.
Trial: NCT04604548
Drug: Oral administration of 100 mg KH176 twice daily
RxNorm normalized name: deferiprone
DrugBank: Deferiprone (DB08826)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Drug: KH176
Trial: NCT04748796
Drug: Landiolol
RxNorm normalized name: Landiolol
DrugBank: Landiolol (DB12212)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Patients randomized to the experimental group will be treated according to the standard of care plus for 2 days with landiolol IV started at a dose of 1 microgram/kg/min and progressively increased every 10 minutes to a maximum of 40 micrograms/kg/min.
Trial: NCT05224336
Drug: Psilocybin
RxNorm normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25mg oral psilocybin
Trial: NCT05224336
Drug: Placebo Niacin
DrugBank: Niacin (DB00627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100mg oral niacin
Trial: NCT04674670
Drug: Bromocriptine Mesylate Capsules
RxNorm normalized name: Bromocriptine Mesylate Capsules
DrugBank: Bromocriptine (DB01200)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Healthy controls and fibromyalgia patients will be administered a single dose of bromocriptine (1.25mg, p.o.) to investigate the effect of transiently increasing the availability of dopamine on fronto-striatal functional connectivity and BOLD response in relation to emotional-motivational pain processing.
Trial: NCT01714115
Drug: Aflibercept
RxNorm normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 2.0 mg Intravitreal Injection, every 2 to 4 weeks
Trial: NCT04660045
Drug: Acalabrutinib
RxNorm normalized name: Acalabrutinib
DrugBank: Acalabrutinib (DB11703)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Acalabrutinib, oral, 100 mg BID, continuous
Trial: NCT04674670
Drug: Amisulpride 400 MG
RxNorm normalized name: amisulpride 400 MG
DrugBank: Amisulpride (DB06288)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Healthy controls will be administered a single dose of amisulpride (400mg, p.o.) to investigate the effect of transiently decreasing the availability of dopamine on fronto-striatal functional connectivity and BOLD response in relation to emotional-motivational pain processing.
Trial: NCT05699135
Drug: Avelumab first-line maintenance
RxNorm normalized name: Avelumab
DrugBank: Avelumab (DB11945)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients with LA/mUC who following 4-6 cycles platinum chemotherapy and have not progressed, received avelumab, recommended dose of 10mg/kg body weight, intravenously administered over 60 minutes every 2 weeks
Trial: NCT04667078
Drug: Cangrelor
RxNorm normalized name: Cangrelor
DrugBank: Cangrelor (DB06441)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: administration of cangrolor by iv befor thrombectomy
Trial: NCT05649579
Drug: Dupilumab
RxNorm normalized name: Dupilumab
DrugBank: Dupilumab (DB12159)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Duplimab was administered according to the guidelines of the atopic dermatitis treatment regimen, which involved the first dose of 600 mg followed by 300 mg every two weeks. Because of comorbidities or the side effects of corticosteroid, some patients used dupilumab in the initial course of treatment, while others added dupilumab when the traditional drugs proved ineffective. The discontinuation was a joint decision between treating dermatologists and patients. Concomitant medicine was decided by clinicians, depending on the assessing of disease status and patients' choices, and reduced according to international guidelines.
Trial: NCT04970238
Drug: Levosimendan
RxNorm normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test drug: drug preparation method: 5ml (12.5mg) levosimendan injection was mixed with 500ml 5% glucose injection, the initial loading dose was 6 µg / kg for 10 minutes, followed by continuous infusion of 0.1 µg/ kg / min for 24 hours.
Trial: NCT05893043
Drug: GSBR-1290
RxNorm normalized name: GSBR-1290
DrugBank: GSBR-1290 (DB18551)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive GSBR-1290 oral capsules.
Trial: NCT01733134
Drug: Tolvaptan
RxNorm normalized name: Tolvaptan
DrugBank: Tolvaptan (DB06212)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tolvaptan 30 mg. tablet for subjects enrolled prior to first 8 hours of coming to an emergency department. Repeated daily up to 5th day.
Trial: NCT05493371
Drug: Empagliflozin 10 MG
RxNorm normalized name: empagliflozin 10 MG
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 10 mg once daily empagliflozin oral tablets for 12 weeks
Trial: NCT04834206
Drug: Nedaplatin
RxNorm normalized name: Nedaplatin
DrugBank: Nedaplatin (DB13145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemotherapy. nedaplatin 100 mg/m2 intravenous at day1, 22, 43 of radiotherapy.
Trial: NCT06180382
Drug: Adalimumab
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administration of adalimumab with optimisation either 80 mg every 14 days by subcutaneous injection, or the same dose of 40 mg every 7 days.
Trial: NCT06180382
Drug: Vedolizumab
RxNorm normalized name: Vedolizumab
DrugBank: Vedolizumab (DB09033)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Strategy B: administration of vedolizumab 300mg by infusion at baseline, 14 days, 42 days and 60 days, followed by a dose of 108mg every fortnight by subcutaneous injection.
Trial: NCT06391411
Drug: anti-VEGF treatment
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal injections of anti-VEGF (Aflibercept 2 mg, 0.05 ml) at a fixed regimen for six months
Trial: NCT06585540
Drug: Amisulpride IV Prevention
DrugBank: Amisulpride (DB06288)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients in this arm will receive Amisulpride 5mg IV as a preventative dose after the induction of anesthesia
Trial: NCT06585540
Drug: Amisulpride IV Treatment
DrugBank: Amisulpride (DB06288)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients in this arm will receive Amisulpride 10mg IV for first-line treatment of Post-Operative Nausea and Vomiting in the post-anesthesia care unit.
Trial: NCT06328426
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The dose of metformin will be 1000 IU /day taken orally. The duration of the intervention will be 4 months.
Trial: NCT05105256
Drug: Platelet-rich plasma
RxNorm normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient will have 1 infiltration of 3mL to 5 mL of PRP on average distributed equally over all the posterior joints affected by arthritis phenomena.Lumbar facet joint injection with PRP will be performed at inclusion.
Trial: NCT05350384
Drug: Methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 g. of methylprednisolone in saline solution 250 cc once a day for 5 days, and one eye drops of Diclofenac per eye 3 times a day for 30 days
Trial: NCT06419946
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: In the experimental treatment arm: a combination of Temozolomide and Lomustine, taken together, two separate pills
Trial: NCT06419946
Drug: Lomustine
RxNorm normalized name: Lomustine
DrugBank: Lomustine (DB01206)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In the experimental treatment arm: a combination of Temozolomide and Lomustine, taken together, two separate pills
Trial: NCT06252662
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: block duration extension additive
Trial: NCT06252662
Drug: Liposomal bupivacaine
RxNorm normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control arm, comparison for block duration with dexmedetomidine
Trial: NCT06167057
Drug: Mitomycin/Gemcitabine
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: UTUC treatment
Trial: NCT06167057
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: UTUC treatment
Trial: NCT05335954
Drug: noradrenaline
RxNorm normalized name: Noradrenaline
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: noradrenaline
Trial: NCT05830695
Drug: human treated dentin matrix
RxNorm normalized name: Matrix
DrugBank: Matrix-M (DB16369)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: human treated dentin matrix is compared with mineral trioxide aggregate in apexogenesis
Trial: NCT05830695
Drug: Mineral Trioxide Aggregate
RxNorm normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mineral trioxide aggregate was used as control
Trial: NCT04596293
Drug: BBT-401-1S or Placebo
RxNorm normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administered by 200mg capsules of BBT-401-1S or placebo
Trial: NCT06026787
Drug: Dapagliflozin 10mg Tab
RxNorm normalized name: DAPAGLIFLOZIN 10MG TAB
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dapagliflozin 10 mg will be added to the standard of care regimen of primary nephrotic syndrome patients
Trial: NCT01047072
Drug: fludarabine phosphate
RxNorm normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01047072
Drug: tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT01047072
Drug: mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given orally
Trial: NCT04745351
Drug: Remdesivir
RxNorm normalized name: remdesivir
DrugBank: Remdesivir (DB14761)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered as Intravenous (IV) infusion once daily
Trial: NCT06217731
Drug: Clonazepam
RxNorm normalized name: Clonazepam
DrugBank: Clonazepam (DB01068)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rivotril 0.25mg once every 24 hours for a month